| Issue Date | Title | Author(s) |
| 1-Mar-2016 | Comparison of nonblood-based and blood-based total CV risk scores in global populations | Gaziano, TA; Abrahams-Gessel, S; Alam, S; Alam, D; Ali, M, et al |
| 9-Jul-2019 | Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial | Steg, PG; Szarek, M; Bhatt, DL; Bittner, VA; Bregeault, M-F, et al |
| 1-Sep-2019 | Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial | White, HD; Steg, PG; Szarek, M; Bhatt, DL; Bittner, VA, et al |
| 14-Sep-2017 | Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016 | Naghavi, M; Abajobir, AA; Abbafati, C; Abbas, KM; Abd-Allah, F, et al |
| 10-Nov-2018 | Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 | Roth, GA; Abate, D; Abate, KH; Abay, SM; Abbafati, C, et al |
| 6-Oct-2016 | Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 | Forouzanfar, MH; Afshin, A; Alexander, LT; Anderson, HR; Bhutta, ZA, et al |
| 10-Nov-2018 | Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 | Stanaway, JD; Afshin, A; Gakidou, E; Lim, SS; Abate, D, et al |
| 16-Sep-2017 | Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 | Gakidou, E; Afshin, A; Abajobir, AA; Abate, KH; Abbafati, C, et al |
| 16-Sep-2017 | Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 | Hay, SI; Abajobir, AA; Abate, KH; Abbafati, C; Abbas, KM, et al |
| 10-Nov-2018 | Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | Kyu, HH; Abate, D; Abate, KH; Abay, SM; Abbafati, C, et al |
| 6-Oct-2016 | Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 | Vos, T; Allen, C; Arora, M; Barber, RM; Bhutta, ZA, et al |
| 8-Oct-2016 | Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015 | Wang, H; Naghavi, M; Allen, C; Barber, RM; Bhutta, ZA, et al |
| 18-May-2017 | Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015 | Barber, RM; Fullman, N; Sorensen, RJD; Bollyky, T; McKee, M, et al |
| 1-Mar-2016 | Hypertension prevalence, awareness, treatment, and control in selected LMIC communities results: from the NHLBI/UHG network of centers of excellence for chronic diseases | Irazola, VE; Gutierrez, L; Bloomfield, G; Carrillo-Larco, RM; Prabhakaran, D, et al |
| 8-Nov-2018 | Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017 | Lozano, R; Fullman, N; Abate, D; Abay, SM; Abbafati, C, et al |
| 15-May-2015 | Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma | Parker, R; Vella, LJ; Xavier, D; Amirkhani, A; Parker, J, et al |
| 1-Mar-2016 | Prevalence of pragmatically defined high CV risk and its correlates in LMIC: a report from 10 LMIC areas in Africa, Asia, and South America | Carrillo-Larco, RM; Miranda, JJ; Li, X; Cui, C; Xu, X, et al |
| 5-Nov-2019 | Risk categorization using New American College of Cardiology/American Heart Association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes | Roe, MT; Li, QH; Bhatt, DL; Bittner, VA; Diaz, R, et al |
| 24-Jul-2019 | The healthfulness of the US packaged food and beverage supply: a cross-sectional study | Baldridge, AS; Huffman, MD; Taylor, F; Xavier, D; Bright, B, et al |